Amishi Y. Shah, M.D.
Department of Genitourinary Medical Oncology, Division of Cancer Medicine
Present Title & Affiliation
Primary Appointment
Associate Professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Education & Training
Degree-Granting Education
| 2010 | Baylor College of Medicine, Houston, TX, USA, MD, Medicine |
| 2006 | Rice University, Houston, TX, USA, BS, Biochemistry and Cell Biology |
Postgraduate Training
| 2013-2016 | Clinical Fellowship, MD Anderson Cancer Center, Houston, TX |
| 2011-2013 | Clinical Residency, University of Pennsylvania, Philadelphia, PA |
| 2010-2011 | Clinical Internship, University of Pennsylvania, Philadelphia, PA |
Board Certifications
| 2016 | American Board of Internal Medicine Hematology |
| 2016 | American Board of Internal Medicine Medical Oncology |
| 2013 | American Board of Internal Medicine |
Experience & Service
Administrative Appointments/Responsibilities
Clinical Research Group Advisor for GU Medical Oncology, Education Liaison, Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 2020 - Present
Morbidity & Mortality Conference Moderator, Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 2019 - Present
Co-director for Genitourinary Medical Oncology Rotation, Hematology Oncology Fellowship Program, Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 2017 - Present
Renal Cell Carcinoma Research & Protocols, Committee Member, Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 2016 - Present
Bladder Cancer Research & Protocols Working Group, Committee Member, Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 2016 - Present
Institutional Committee Activities
Division of Cancer Medicine Representative, MD Anderson Institutional Diversity, Equity, and Inclusion Committee, 2021 - 2023
Committee Co-Chair, Preventing Burnout and Promoting Resiliency in Junior Faculty Initiative, Division of Cancer Medicine, MDACC, 2020 - Present
Clinical Arm Core Team and Resources Group Lead, MD Anderson Institutional Immune Oncology Toxicity Initiative, 2019 - 2023
Core Leadership Working Group, MD Anderson Institutional Immune Oncology Toxicity Initiative, 2019 - 2023
Committee Member, Update on Management of GU Malignancies Yearly Conference, MDACC, 2016 - Present
Committee Member, Hematology - Medical Oncology Fellowship Steering Committee, MDACC, 2014 - Present
Honors & Awards
| 2022 | Nominated for The UT System Regents’ Outstanding Teaching Award, The University of Texas System Regents |
| 2022 | UT MD Anderson Cancer Center, Division of Cancer Medicine, Hematology-Oncology Fellowship Leadership in Education Award, UT MD Anderson Cancer Center |
| 2022 | Nominated for Gerald P. Bodey “Excellence in Education” Award, Division of Cancer Medicine, MD Anderson Cancer Center |
| 2021 | "SoMe" Social Medial Award for most influential article of the issue - "Outcomes of Patients with Metastatic Renal Cell Carcinoma Treated with Targeted Therapy After Immuno-Oncology Checkpoint Inhibitors, European Urology Oncology |
| 2021 | Nominated for the DoCM Melvin L. Samuels Award for Excellence in Patient Care, The University of Texas MD Anderson Cancer Center |
| 2020 | Nominated for Gerald P. Bodey “Excellence in Education” Award, Division of Cancer Medicine, MD Anderson Cancer Center |
| 2019 | APRN Fellows' Choice Award for Outstanding Faculty Preceptor, MD Anderson Cancer Center |
| 2019 | FY 2019 Top Performer – Top 10% Nationally on CAHPS scores, MD Anderson Cancer Center |
| 2017 | FY 2017 Top performer Top 1 Percentile Nationally on CAHPS scores, MD Anderson Cancer Center |
| 2017 | Teaching Dept of the Year (GU) for Hematology - Medical Oncology, MD Anderson Cancer Center |
| 2015 | 2nd Year Fellow of the Year Award, LBJ Hospital, MD Anderson Cancer Center |
| 2015 | Fellows Recognition Program Nomination, NCCN Annual Conference |
| 2014 | Clifton D. Howe Award for Clinical Excellence, MD Anderson Cancer Center |
| 2013 | Conquer Cancer Foundation Merit Award, American Society of Clinical Oncology |
Professional Memberships
Selected Publications
Peer-Reviewed Articles
- Lee CH, Shah AY, Rasco D, Rao A, Taylor MH, Di Simone C, Hsieh JJ, Pinto A, Shaffer DR, Girones Sarrio R, Cohn AL, Vogelzang NJ, Bilen MA, Gunnestad Ribe S, Goksel M, Tennøe ØK, Richards D, Sweis RF, Courtright J, Heinrich D, Jain S, Wu J, Schmidt EV, Perini RF, Kubiak P, Okpara CE, Smith AD, Motzer RJ. Lenvatinib plus pembrolizumab in patients with either treatment-naive or previously treated metastatic renal cell carcinoma (Study 111/KEYNOTE-146): a phase 1b/2 study. Lancet Oncol 22(7):946-958, 2021. e-Pub 2021. PMID: 34143969.
- Andreev-Drakhlin AY, Egoryan G, Shah AY, Msaouel P, Alhalabi O, Gao J. The Evolving Treatment Landscape of Advanced Urothelial Carcinoma. Curr Opin Oncol 33(3):221-230, 2021. PMID: 33818541.
- Laccetti AL, Garmezy B, Xiao L, Economides M, Venkatesan A, Gao J, Jonasch E, Corn P, Zurita-Saavedra A, Brown LC, Kao C, Kinsey EN, Gupta RT, Harrison MR, Armstrong AJ, George DJ, Tannir N, Msaouel P, Shah A, Zhang T, Campbell MT. Combination anti-angiogenic tyrosine kinase inhibition and anti-PD1 immunotherapy in metastatic renal cell carcinoma: A retrospective analysis of safety, tolerance and clinical outcomes. Cancer Med 10(7):2341-2349, 2021. e-Pub 2021. PMID: 33650321.
- Choueiri TK, Powles T, Burotto M, Escudier B, Bourlon MT, Zurawski B, Oyervides Juárez VM, Hsieh JJ, Basso U, Shah AY, Suárez C, Hamzaj A, Goh JC, Barrios C, Richardet M, Porta C, Kowalyszyn R, Feregrino JP, Zolnierek J, Pook D, Kessler ER, Tomita Y, Mizuno R, Bedke J, Zhang J, Maurer MA, Simsek B, Ejzykowicz F, Schwab GM, Apolo AB, Motzer RJ, CheckMate 9ER Investigators. Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma. N Engl J Med 384(9):829-841, 2021. PMID: 33657295.
- McGregor BA, Campbell MT, Xie W, Farah S, Bilen MA, Schmidt AL, Sonpavde GP, Kilbridge KL, Choudhury AD, Mortazavi A, Shah AY, Venkatesan AM, Bubley GJ, Siefker-Radtke AO, McKay RR, Choueiri TK. Results of a multicenter, phase 2 study of nivolumab and ipilimumab for patients with advanced rare genitourinary malignancies. Cancer 127(6):840-849, 2021. e-Pub 2020. PMID: 33216356.
- Graham J, Shah AY, Wells JC, McKay RR, Vaishampayan U, Hansen A, Donskov F, Bjarnason GA, Beuselinck B, De Velasco G, Iafolla M, Duh MS, Huynh L, Chang R, Zanotti G, Ramaswamy K, Choueiri TK, Tannir NM, Heng DYC. Outcomes of Patients with Metastatic Renal Cell Carcinoma Treated with Targeted Therapy After Immuno-oncology Checkpoint Inhibitors. Eur Urol Oncol 4(1):102-111, 2021. e-Pub 2019. PMID: 31786162.
- Gao J, Navai N, Alhalabi O, Siefker-Radtke A, Campbell MT, Tidwell RS, Guo CC, Kamat AM, Matin SF, Araujo JC, Shah AY, Msaouel P, Corn P, Wang J, Papadopoulos JN, Yadav SS, Blando JM, Duan F, Basu S, Liu W, Shen Y, Zhang Y, Macaluso MD, Wang Y, Chen J, Zhang J, Futreal A, Dinney C, Allison JP, Goswami S, Sharma P. Neoadjuvant PD-L1 plus CTLA-4 blockade in patients with cisplatin ineligible operable high-risk urothelial carcinoma. Nat Med 26(12):1845-1851, 2020. e-Pub 2020. PMID: 33046869.
- Shah AY, Kotecha RR, Lemke EA, Chandramohan A, Chaim JL, Msaouel P, Xiao L, Gao J, Campbell MT, Zurita AJ, Wang J, Corn PG, Jonasch E, Motzer RJ, Sharma P, Voss MH, Tannir NM. Outcomes of patients with metastatic clear-cell renal cell carcinoma treated with second-line VEGFR-TKI after first-line immune checkpoint inhibitors. Eur J Cancer 114:67-75, 2019. e-Pub 2019. PMID: 31075726.
- Alhalabi O, Rafei H, Shah AY, Siefker-Radtke A, Campbell M, Gao J.. Targeting advanced urothelial carcinoma-developing strategies. Current Opinion in Oncology 31(3):207-215, 2019. PMID: 30844889.
- Lemke EA, Shah AY, Campbell M, Tannir NM. Real-World Experience With Cabozantinib in Metastatic Clear Cell Renal Cell Carcinoma: A Retrospective Analysis. J Adv Pract Oncol 10(4):333-339, 2019. e-Pub 2019. PMID: 33343982.
- Alhalabi O, Shah AY, Lemke EA, Gao J. Current and Future Landscape of Immune Checkpoint Inhibitors in Urothelial Cancer. Oncology (Williston Park) 33(1):11-8, 2019. PMID: 30731013.
- Shah AY, Karam JA, Malouf GG, Rao P, Lim ZD, Jonasch E, Xiao L, Gao J, Vaishampayan UN, Heng DY, Plimack ER, Guancial EA, Fung C, Lowas SR, Tamboli P, Sircar K, Matin SF, Kimryn Rathmell W, Wood CG, Tannir NM. Management and outcomes of patients with renal medullary carcinoma: a multicentre collaborative study. BJU Int 120(6):782-792, 2017. e-Pub 2016. PMID: 27860149.
- Maiti A, Nemati-Shafaee M, Msaouel P, Pagliaro LC, Jonasch E, Tannir NM, Shah AY. Phase 2 Trial of Capecitabine, Gemcitabine, and Bevacizumab in Sarcomatoid Renal-Cell Carcinoma. Clin Genitourin Cancer 17:S1558-7673(17)30238-0, 2017. e-Pub 2017. PMID: 28870517.
- Campbell MT, Shah AY, Matin SF, Siefker-Radtke AO. Optimizing management of upper tract urothelial carcinoma. Urol Oncol 35(7):492-498, 2017. e-Pub 2017. PMID: 28579283.
- Malouf GG, Joseph RW, Shah AY, Tannir NM. Non-clear cell renal cell carcinomas: biological insights and therapeutic challenges and opportunities. Clin Adv Hematol Oncol 15(5):409-418, 2017. PMID: 28591094.
Editorials
- Shah AY, Tannir NM. Surveillance or Systemic Therapy? An Editorial Re: Observation After Cytoreductive Nephrectomy in Patients with Synchronous not Completely Resected Metastases of Renal Cell Carcinoma. Urology 109:132, 2017. PMID: 28867144.
- Shah AY, Gao J, Siefker-Radtke AO. Five new therapies or just one new treatment? A critical look at immune checkpoint inhibition in urothelial cancer. Immunotherapy 9(10):781-784, 2017. PMID: 28877627.
Patient Reviews
CV information above last modified May 01, 2024